Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of B/F/TAF Re-start in HIV Patients Discontinuing NNRTI Regimens
NCT06830668Phase 4Not yet recruiting
- Sponsor
- CNAIDS
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by CNAIDS. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06830668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830668.